

Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

Phyllis A. Gimotty^{1,*}, Jacob E. Till^{2,*}, Shirsa Udgata³, Naomi Takenaka³, Stephanie S. Yee², Michael J. LaRiviere⁴, Mark H. O'Hara², Kim A. Reiss², Peter O'Dwyer², Bryson W. Katona⁵, Daniel Herman⁶, Erica L. Carpenter^{2,**} and Kenneth S. Zaret^{3,**}

¹Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

²Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

³Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

⁴Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

⁵Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

⁶Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA

*These authors contributed equally to this work

**Co-corresponding authors

Published: November 02, 2022

Copyright: © 2022 Gimotty et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Authors Kenneth S. Zaret and Erica L. Carpenter contributed equally as corresponding authors. The footnote to the author list indicating both individuals as co-corresponding authors was unintentionally omitted. The proper footnote is shown below:

**Co-corresponding authors

In addition, the paper's title has been corrected to read, 'THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma.' The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2021; 12:2266–2272. <https://doi.org/10.18632/oncotarget.28099>